Agile Therapeutics, Inc. (AGRX) Financial Statements (2023 and earlier)

Company Profile

Business Address 500 COLLEGE ROAD EAST
PRINCETON, NJ 08540-6635
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,24619,14354,47134,4797,85135,952
Cash and cash equivalents5,24619,14314,46334,4797,85135,952
Short-term investments   40,008   
Receivables3,3771,533865   
Inventory, net of allowances, customer advances and progress billings1,332966100   
Inventory1,332966100   
Prepaid expense1,4032,2831,449840607762
Other undisclosed current assets   (100)   
Total current assets:11,35823,92556,78535,3198,45836,714
Noncurrent Assets
Operating lease, right-of-use asset695949138 
Property, plant and equipment17712,44714,24314,04413,91613,863
Other noncurrent assets2,0122,0121,896 1818
Other undisclosed noncurrent assets    177  
Total noncurrent assets:2,88415,40816,27714,22113,93413,881
TOTAL ASSETS:14,24239,33373,06249,54022,39250,595
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,64212,2707,2153,6232,2183,636
Accounts payable7,7348,7073,8671,8198752,784
Accrued liabilities3,9083,5633,3481,8041,343852
Debt1,42616,833 172 10,607
Derivative instruments and hedges, liabilities      29
Other undisclosed current liabilities319175138   
Total current liabilities:13,38729,2787,3533,7952,21814,272
Noncurrent Liabilities
Long-term debt and lease obligation:  784    
Liabilities, other than long-term debt6,400     
Operating lease, liability466784  
Derivative instruments and hedges, liabilities5,934     
Other undisclosed noncurrent liabilities  (784)16,381   
Total noncurrent liabilities:6,40078416,381   
Total liabilities:19,78730,06223,7343,7952,21814,272
Equity
Equity, attributable to parent(5,545)9,27149,32845,74520,17436,323
Common stock 4129733
Additional paid in capital403,153396,376361,539306,108261,722258,092
Accumulated other comprehensive income   3   
Accumulated deficit(408,702)(387,117)(312,223)(260,370)(241,551)(221,772)
Total equity:(5,545)9,27149,32845,74520,17436,323
TOTAL LIABILITIES AND EQUITY:14,24239,33373,06249,54022,39250,595

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues10,8844,101749   
Cost of revenue(6,836)(10,718)(282)   
Provision for loan, lease, and other losses     
Gross profit:4,048(6,617)467   
Operating expenses(56,604)(64,388)(49,520)(18,858)(19,535)(26,811)
Operating loss:(52,556)(71,005)(49,053)(18,858)(19,535)(26,811)
Nonoperating income (expense)22,469(3,889)(2,800)252(721)(1,493)
Investment income, nonoperating8025309252366282
Interest and debt expense(3,131)(3,914)(3,109) (1,116)(1,918)
Loss from continuing operations before equity method investments, income taxes:(33,218)(78,808)(54,962)(18,606)(21,372)(30,222)
Other undisclosed income from continuing operations before income taxes3,131 3,109 1,1161,918
Loss from continuing operations before income taxes:(30,087)(78,808)(51,853)(18,606)(20,256)(28,304)
Income tax benefit 4,675   477 
Loss from continuing operations:(25,412)(78,808)(51,853)(18,606)(19,779)(28,304)
Loss before gain (loss) on sale of properties:(78,808)(51,853)(18,606)(19,779)(28,304)
Other undisclosed net income  3,914    
Net loss available to common stockholders, diluted:(25,412)(74,894)(51,853)(18,606)(19,779)(28,304)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(25,412)(74,894)(51,853)(18,606)(19,779)(28,304)
Comprehensive loss:(25,412)(74,894)(51,853)(18,606)(19,779)(28,304)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (3)3   
Comprehensive loss, net of tax, attributable to parent:(25,412)(74,897)(51,850)(18,606)(19,779)(28,304)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: